Abdera Therapeutics
Latest round
- Series A
Last raised
- Apr 2023
Total raised
- Undisclosed
Investors
- 9
About Abdera Therapeutics
Founded in 2020 in Vancouver, Canada, Abdera Therapeutics Inc. is dedicated to advancing cancer therapies through its research and development efforts.Abdera Therapeutics specializes in advanced cancer treatment solutions through its proprietary ROVEr™ platform, which integrates antibody engineering and radiotherapeutics to develop novel radiopharmaceuticals. The primary focus of this platform is on constructing targeted therapies that deliver radionuclide payloads, either alpha or beta-emitting, to a wide array of solid tumor targets, enhancing therapeutic effects while minimizing systemic toxicities. The company’s lead product, ABD-147, is currently undergoing a Phase 1 clinical trial for small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Targeted primarily at oncological healthcare providers, research institutions, and clinical trial participants, Abdera aims to address critical unmet needs in cancer treatment.Revenue generation for Abdera Therapeutics is driven by its clinical development programs, specifically through partnerships with healthcare institutions and pharmaceutical companies involved in cancer treatment. Transactions occur primarily in a B2B context, where Abdera collaborates with clinical research organizations and healthcare providers to facilitate the development and potential commercialization of its radiotherapeutics. These collaborations often involve upfront payments for access to proprietary technology, milestone payments as products advance through clinical trials, and royalties on future sales of successful therapies.00 mn, the company will utilize these funds to further develop its ROVEr™ platform and accelerate the testing of its new cancer medicines. Abdera plans to expand its product offerings and target markets, particularly within North America and Europe, to meet the growing demand for advanced cancer therapies. The firm is focused on solidifying partnerships with healthcare providers and research institutions to enhance the reach and impact of its innovative treatment solutions.
Who invested in Abdera Therapeutics
9 investors across 2 rounds
See all investors in Abdera Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Abdera Therapeutics
Who invested in Abdera Therapeutics?
Abdera Therapeutics has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Abdera Therapeutics raised?
Abdera Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Abdera Therapeutics last raise money?
Abdera Therapeutics's most recent round on record is a Series A, in Apr 2023.
What does Abdera Therapeutics do?
Founded in 2020 in Vancouver, Canada, Abdera Therapeutics Inc.
Where is Abdera Therapeutics headquartered?
Abdera Therapeutics is headquartered in Vancouver, Canada.
Which VCs invest in companies like Abdera Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Abdera Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Abdera Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.